For innovation companies, highly differentiated and technologically advanced biobetters offer the greatest potential to mitigate the risks associated with the introduction of biosimilars, as they can be approved before the patent expires and have blockbuster potential.
Related Articles Read More >

9 R&D developments this week: Lilly builds major R&D center, Stratolaunch tests hypersonic craft, IBM chief urges AI R&D funding

Why science ethicists are sounding skepticism and alarm on ‘de-extinction’

ALAFIA system speeds complex molecular simulations for University of Miami drug research
